CompletedPHASE1, PHASE2NCT03513328
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Studying Autosomal dominant aplasia and myelodysplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Florida
- Principal Investigator
- Biljana Horn, MDUniversity of Florida
- Intervention
- Thiotepa--single daily dose(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 39 years · All sexes
- Timeline
- 2018 – 2023
Study locations (1)
- UF Health Shands Children's Hospital, Gainesville, Florida, United States
Collaborators
Live Like Bella Pediatric Cancer Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03513328 on ClinicalTrials.govOther trials for Autosomal dominant aplasia and myelodysplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06090669Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyNational Cancer Institute (NCI)
- RECRUITINGNANCT04781790French National Registry of Bone Marrow FailuresAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT02958462Pre-myeloid Cancer and Bone Marrow Failure Clinic StudyMayo Clinic
- RECRUITINGNCT01905826Natural History Study of GATA2 Deficiency and Related DisordersNational Institute of Allergy and Infectious Diseases (NIAID)
See all trials for Autosomal dominant aplasia and myelodysplasia →